BRAF V600EPost-hoc analysisESMO 2025來源:人工整理

1L EC+mFOLFOX6 → subsequent tx

關鍵結果PFS2: 20.7 vs 12.9 mo (sequential EC)

一線即用 EC+化療 > 序貫式先化療再 EC。「最佳治療優先」獲證實

詳細證據整理

Subsequent Therapies in the Phase 3 BREAKWATER Study of First-Line EC + mFOLFOX6 in Patients with BRAF V600E-Mutant mCRC

Authors: Kopetz S, et al.
Presented at: ESMO 2025 (Poster)
Study: BREAKWATER (Phase 3)
Note: This is a conference poster presentation. No peer-reviewed journal full text is available.

Key Findings

Subsequent Therapy in the Control Arm

  • 71.9% of control arm patients received a subsequent BRAF inhibitor-based therapy
  • 55.4% of control arm patients received encorafenib + cetuximab (EC) as subsequent therapy

PFS2 (Progression-Free Survival After Next Line of Therapy)

Measure EC+mFOLFOX6 (1L) Control → EC (1L→2L)
Median PFS2 20.7 months 12.9 months

These data demonstrate that first-line use of EC+mFOLFOX6 results in superior cumulative disease control compared to the strategy of using chemotherapy first and reserving EC for the second line.

Surgical Conversion

  • Surgical conversion rate with EC+mFOLFOX6: 5.2%
  • Complete resection rate: 3.0%

本頁僅供醫療專業人員教育與臨床參考,不構成醫療建議;臨床決策請以原始文獻與現行指引為準。

讀者討論

讀者留言是個人意見,不是本站的文獻整理,也沒有經過醫學審核。

載入留言中…

  • GuidelineJNCCN 2026來源:摘要

    NCCN Colon Cancer v3.2026(Guidelines Insights)

    BRAF V600E 晚期治療推薦更新, 晚期治療章節依 biomarker 重組; 新增 fluoropyrimidine 前 DPYD 檢測; 依近期試驗更新非轉移性輔助治療

    NCCN 結腸癌 v3.2026 依 biomarker 重組晚期治療章節,並特別更新 BRAF V600E 推薦,承接 BREAKWATER 證據;另新增化療前 DPYD 檢測建議。Insights 摘要未列推薦等級,細節需對照指引全文

  • Phase 3 (Cohort 3)ASCO GI 2026來源:人工整理

    EC+FOLFIRI vs FOLFIRI±bev (1L)

    ORR 64.4% vs 39.2%, OR 2.76; 肝 mets ORR 79.1%

    FOLFIRI 也行——提供第二個化療骨幹選擇,特別適合 oxaliplatin 禁忌

  • Biomarker (exploratory)ESMO 2025來源:人工整理

    EC+mFOLFOX6 vs EC vs SOC

    C2D15 D/ND: 67.1% vs 45.2% vs 37.5%; resistance 6.6% vs 37.9%

    化療骨幹壓制抗藥性克隆——EC+chemo 優於 EC alone 的分子機制

  • Phase 3 RCTNat Med 2025來源:人工整理

    EC+mFOLFOX6 vs SOC (1L)

    ORR 60.9% vs 40.0%, OR 2.44

    BREAKWATER 首報:一線 EC+化療 ORR 達 61%,FDA 加速核准

看 BRAF V600E 的全部文獻